

Manuel Hernandez-Guerra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4061279/publications.pdf>

Version: 2024-02-01

76
papers

4,116
citations

159358

30
h-index

114278

63
g-index

84
all docs

84
docs citations

84
times ranked

4758
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis C diagnosis slowdown in high-prevalence groups and using decentralised diagnostic strategies during the COVID-19 pandemic. <i>Revista Espanola De Enfermedades Digestivas</i> , 2022, , .	0.1	2
2	Primary biliary cholangitis and SARS-CoV-2 infection: incidence, susceptibility and outcomes. <i>Gut</i> , 2022, 71, 2138-2140.	6.1	9
3	Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 131-143.	1.9	9
4	Transcriptional response of aldosterone target genes in the rat and human distal colon during hepatic cirrhosis. <i>FASEB Journal</i> , 2022, 36, .	0.2	0
5	Appropriateness of high-priority criteria and safety of endoscopy procedures during the COVID-19 lockdown. <i>PLoS ONE</i> , 2022, 17, e0267112.	1.1	0
6	Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. <i>Gastroenterology</i> , 2021, 160, 193-205.e10.	0.6	97
7	Hepatitis C virus media coverage favorably impacts on antibody testing in the non-interferon era. <i>Journal of Public Health</i> , 2021, 43, 385-391.	1.0	4
8	Increasing the low residue diet to 3 days does not improve the bowel cleansing in hard to prepare patients: Post hoc analysis of a randomized controlled trial. <i>GastroenterologÃa Y HepatologÃa (English Edition)</i> , 2021, 44, 183-190.	0.0	0
9	An Enhanced High-Volume Preparation for Colonoscopy Is Not Better Than a Conventional Low-Volume One in Patients at Risk of Poor Bowel Cleansing: A Randomized Controlled Trial. <i>Frontiers in Medicine</i> , 2021, 8, 654847.	1.2	2
10	Increasing the low residue diet to 3 days does not improve the bowel cleansing in hard to prepare patients: Post hoc analysis of a randomized controlled trial. <i>GastroenterologÃa Y HepatologÃa</i> , 2021, 44, 183-190.	0.2	2
11	Carotid Plaque Assessment Reclassifies Patients with Inflammatory Bowel Disease into Very-High Cardiovascular Risk. <i>Journal of Clinical Medicine</i> , 2021, 10, 1671.	1.0	8
12	Usefulness of prioritization systems during the resumption of gastrointestinal endoscopy activity during the COVID-19 pandemic. <i>Endoscopy</i> , 2021, 53, 662-663.	1.0	2
13	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsyâ€proven nonalcoholic fatty liver disease subjects. <i>Liver International</i> , 2021, 41, 2076-2086.	1.9	13
14	El paciente tratado de hepatitis C como fuente potencial de derivaciÃ³n de nuevos casos. <i>GastroenterologÃa Y HepatologÃa</i> , 2021, 44, 704-710.	0.2	0
15	Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study. <i>American Journal of Gastroenterology</i> , 2021, 116, 2250-2257.	0.2	14
16	Endometriosis polipoide simulando una neoplasia avanzada de ovario con infiltraciÃ³n de la pared intestinal: descripciÃ³n ecoendoscÃ³pica del caso. <i>GastroenterologÃa Y HepatologÃa</i> , 2021, 44, 433-434.	0.2	0
17	Insulin Resistance Is Not Increased in Inflammatory Bowel Disease Patients but Is Related to Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 3062.	1.0	6
18	Telemedicine and decentralized hepatitis C treatment as a strategy to enhance retention in care among people attending drug treatment centres. <i>International Journal of Drug Policy</i> , 2021, 94, 103235.	1.6	10

#	ARTICLE	IF	CITATIONS
19	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. <i>Journal of Hepatology</i> , 2021, 75, 342-350.	1.8	28
20	QRISK3 Performance in the Assessment of Cardiovascular Risk in Patients with Inflammatory Bowel Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 4102.	1.0	1
21	Hepatitis C-treated patients as a potential source for referral of new cases. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2021, 44, 704-704.	0.0	0
22	Prediction of liver stiffness by serum indexes in HCV-infected patients with or without HIV coinfection. <i>Medicine (United States)</i> , 2021, 100, e27838.	0.4	2
23	Estimated glomerular filtration rate by formulas in patients with cirrhosis: An unreliable procedure. <i>Liver International</i> , 2021, , .	1.9	3
24	Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review. <i>Scientific Reports</i> , 2021, 11, 24133.	1.6	13
25	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020, 174, 104694.	1.9	39
26	Patients with suboptimal hepatitis B virus diagnostic characterization are at risk of liver fibrosis progression. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 426-432.	0.8	1
27	Electronic Alerts as a Simple Method for Amplifying the Yield of Hepatitis C Virus Infection Screening and Diagnosis. <i>American Journal of Gastroenterology</i> , 2020, 115, 9-12.	0.2	12
28	International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis. <i>Liver International</i> , 2020, 40, 1467-1476.	1.9	15
29	Risk of liver fibrosis progression in patients with suboptimal diagnosis of hepatitis C virus infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 528-534.	0.8	5
30	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. <i>Journal of Hepatology</i> , 2020, 73, 1082-1091.	1.8	112
31	Evaluación de la precisión diagnóstica del sistema Cobas 6800 para la detección de los niveles de viremia del virus de la hepatitis C a partir de muestras de gotas de sangre seca en papel de filtro. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 267-274.	0.3	6
32	Pre-Procedural Antibody Testing for SARS-CoV-2 in routine endoscopic practice. <i>Revista Española De Enfermedades Digestivas</i> , 2020, 113, 116-118.	0.1	6
33	Sexual behaviour and poor hygiene are related to recent hepatitis a virus community outbreaks. <i>Revista Española De Enfermedades Digestivas</i> , 2020, 112, 448-455.	0.1	4
34	Preemptive TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study. <i>Hepatology</i> , 2019, 69, 282-293.	3.6	144
35	Chronic kidney disease staging with cystatin C or creatinine-based formulas: flipping the coin. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 287-294.	0.4	22
36	Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfecting with human immunodeficiency virus-1 in Spain. <i>PLoS ONE</i> , 2019, 14, e0225061.	1.1	4

#	ARTICLE	IF	CITATIONS
37	Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. <i>Journal of Hepatology</i> , 2019, 71, 666-672.	1.8	67
38	Predictive factors for not undergoing RNA testing in patients found to have hepatitis C serology and impact of an automatic alert. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1117-1123.	1.0	19
39	Impact of a 1-day versus 3-day low-residue diet on bowel cleansing quality before colonoscopy: a randomized controlled trial. <i>Endoscopy</i> , 2019, 51, 628-636.	1.0	40
40	Gap junctions in liver disease: Implications for pathogenesis and therapy. <i>Journal of Hepatology</i> , 2019, 70, 759-772.	1.8	30
41	Eliminaci3n de la hepatitis C. Documento de posicionamiento de la Asociaci3n Espa3ola para el Estudio del H3gado (AEEH). <i>Gastroenterolog3a Y Hepatolog3a</i> , 2019, 42, 579-592.	0.2	25
42	Enfermedad hep3tica por alcohol. Gu3as de pr3ctica cl3nica. Documento de consenso auspiciado por la AEEH. <i>Gastroenterolog3a Y Hepatolog3a</i> , 2019, 42, 657-676.	0.2	12
43	Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD). <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 264-269.	0.1	16
44	Documento de consenso. Manejo de la enfermedad hep3tica grasa no alcoh3lica (EHGNA). Gu3a de pr3ctica cl3nica. <i>Gastroenterolog3a Y Hepatolog3a</i> , 2018, 41, 328-349.	0.2	71
45	Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. <i>Hepatology</i> , 2018, 67, 612-622.	3.6	55
46	Risk factors for inadequate bowel preparation: a validated predictive score. <i>Endoscopy</i> , 2017, 49, 536-543.	1.0	51
47	Comparison of Two Intensive Bowel Cleansing Regimens in Patients With Previous Poor Bowel Preparation: A Randomized Controlled Study. <i>American Journal of Gastroenterology</i> , 2017, 112, 951-958.	0.2	51
48	Effect of season and sunlight on viral kinetics during hepatitis C virus therapy. <i>BMJ Open Gastroenterology</i> , 2017, 4, e000115.	1.1	6
49	Risk of Advanced Neoplasia in First-Degree Relatives with Colorectal Cancer: A Large Multicenter Cross-Sectional Study. <i>PLoS Medicine</i> , 2016, 13, e1002008.	3.9	20
50	Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. <i>Journal of Hepatology</i> , 2016, 65, 532-542.	1.8	115
51	Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. <i>Gastroenterology</i> , 2016, 150, 1160-1170.e3.	0.6	232
52	Impact of age- and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening. <i>Digestive and Liver Disease</i> , 2016, 48, 542-551.	0.4	23
53	Contribution of Cyclooxygenase End Products and Oxidative Stress to Intrahepatic Endothelial Dysfunction in Early Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016, 11, e0156650.	1.1	37
54	Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival. <i>United European Gastroenterology Journal</i> , 2015, 3, 284-293.	1.6	4

#	ARTICLE	IF	CITATIONS
55	High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. <i>Annals of Hepatology</i> , 2015, 14, 477-86.	0.6	0
56	Role of gap junctions modulating hepatic vascular tone in cirrhosis. <i>Liver International</i> , 2014, 34, 859-868.	1.9	22
57	Rate of Detection of Advanced Neoplasms in Proximal Colon by Simulated Sigmoidoscopy vs Fecal Immunochemical Tests. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1708-1716.e4.	2.4	13
58	Equivalency of Fecal Immunochemical Tests and Colonoscopy in Familial Colorectal Cancer Screening. <i>Gastroenterology</i> , 2014, 147, 1021-1030.e1.	0.6	52
59	Chronic intermittent hypoxia aggravates intrahepatic endothelial dysfunction in cirrhotic rats. <i>Hepatology</i> , 2013, 57, 1564-1574.	3.6	21
60	Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. <i>Hepatology</i> , 2013, 58, 2079-2088.	3.6	48
61	Immunogenicity and Acceptance of Influenza A (H1N1) Vaccine in a Cohort of Chronic Hepatitis C Patients Receiving Pegylated-Interferon Treatment. <i>PLoS ONE</i> , 2012, 7, e48610.	1.1	2
62	Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome. <i>Blood</i> , 2010, 115, 388-395.	0.6	43
63	Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. <i>Journal of Gastroenterology</i> , 2010, 45, 703-712.	2.3	105
64	Acute portal vein thrombosis unrelated to cirrhosis: A prospective multicenter follow-up study. <i>Hepatology</i> , 2010, 51, 210-218.	3.6	458
65	Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 1062-1067.	0.8	15
66	Etiology, Management, and Outcome of the Budd-Chiari Syndrome. <i>Annals of Internal Medicine</i> , 2009, 151, 167.	2.0	422
67	Extrahepatic Portal Vein Thrombosis. <i>Seminars in Liver Disease</i> , 2008, 28, 282-292.	1.8	115
68	Pharmacological Reduction of Portal Pressure and Long-Term Risk of First Variceal Bleeding in Patients with Cirrhosis. <i>American Journal of Gastroenterology</i> , 2006, 101, 506-512.	0.2	228
69	Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome. <i>Hepatology</i> , 2006, 43, 27-33.	3.6	39
70	Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis. <i>Hepatology</i> , 2006, 43, 34-41.	3.6	31
71	Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. <i>Hepatology</i> , 2006, 43, 485-491.	3.6	106
72	Increased Hepatic Resistance. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, S131-S137.	1.1	55

#	ARTICLE	IF	CITATIONS
73	Portal Hypertension Secondary to Myelofibrosis: A Study of Three Cases. American Journal of Gastroenterology, 2005, 100, 2355-2358.	0.2	30
74	PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology, 2004, 40, 1197-1202.	3.6	142
75	Are there Predictive Factors of Severe Liver Fibrosis in Morbidly Obese Patients with Non-alcoholic Steatohepatitis?. Obesity Surgery, 2001, 11, 254-257.	1.1	80
76	Gene expression of tumor necrosis factor [alpha] and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology, 2001, 34, 1158-1163.	3.6	572